Colon cancer organoids using monoclonal organoids established in four different lesions of one cancer patient reveal tumor heterogeneity and different real-time responsiveness to anti-cancer drugs

Biomed Pharmacother. 2022 Aug:152:113260. doi: 10.1016/j.biopha.2022.113260. Epub 2022 Jun 9.


Organoid culture technique has been taking center stage as a next-generation ex-vivo model due to advancement of stem cell research techniques. The importance of the laboratory-based ex vivo model has increasingly been recognized for recapitulating histological, and physioglocal conditions of in vivo microenviorment. Accordingly, the use of this technique has also broadened the understanding of intratumoral heterogeneity which is closely associated with varied drug responses observed in patients. Likewise, studies on heterogeneity within a single tumor tissue have drawn much attention. Here, we isolated 15 single clones from 4 tumor organoid lines from 1 patient at a primary passage from one patient. Each organoid line showed variable alterations in both genotype and phenotype. Furthermore, our methodological approach on drug test employing a high-throughput screening system enabled us to pinpoint the optimal time frame for anti-cancer drugs within a single tumor. We propose that our method can effectively reveal the heterogeneity of time-point in drug response, and the most optimal therapeutic strategies for individual patient.

Keywords: Conlon cancer organoid; High-throughput screening, Precision medicine; Image-based drug responsiveness tracing; Intratumor heterogeneity; Subclonal characterization.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Colonic Neoplasms* / drug therapy
  • Colonic Neoplasms* / pathology
  • Drug Screening Assays, Antitumor
  • High-Throughput Screening Assays
  • Humans
  • Organoids / pathology


  • Antineoplastic Agents